Extended Data Fig. 7: Anti-pre-TCR ADCs have no deleterious effect on normal T cell development.
From: Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia
(A) Schematic diagram of experimental design for anti-pTα-ADC treatment of humanized mice. NSG mice transplanted with human CB HPCs received i.p. injections of either DM1-conjugated anti-pTα monoclonal antibody or a DM1-conjugated isotype-matched control, twice a week for 3 weeks, starting at 9 (B-D; n = 5 mice per group) or 21 (E-G; n = 3 mice per group) weeks post-transplant. (B, E) Kinetics of human T (left panels) and B cell (right panels) reconstitution of peripheral blood of mice treated as shown in (A). (C, F). Percentages of T and B cells among human CD45+ cells recovered from the spleens of treated mice at week 2 (C) or week 3 (F) post-treatment. (D, G) Percentages of human T-cell progenitors expressing the pre-TCR, or placed up (pre-pre-TCR) or downstream (post-pre-TCR) of pre-TCR expression, recovered from the thymus of treated mice at week 2 (D) or week 3 (G) post-treatment. Data are shown as mean ± s.e.m. cell percentages analysed by two-way ANOVA with Sidak’s multiple comparison test: ordinary (C, D, F, G) or with Geisser-Greenhouse correction (B and E).
